WE'RE DEDICATED TO FINDING ATREATMENT FOR SMA
In collaboration with Astellas, Cytokinetics is developing reldesemtiv (CK-2127107), a next-generation fast skeletal muscle troponin activator (FSTA) as a potential treatment for people living with debilitating diseases and conditions associated with neuromuscular or non-neuromuscular dysfunction, muscular weakness, and/or muscle fatigue.
Reldesemtiv is an investigational drug candidate intended to slow the rate of calcium release from the regulatory troponin complex of fast skeletal muscle fibers. Reldesemtiv is a next-generation skeletal muscle compound that may improve muscle function and physical performance in people with SMA, COPD, elderly adults with limited mobility and ALS.
Reldesemtiv has been the subject of five completed Phase 1 clinical trials in healthy volunteers, which evaluated safety, tolerability, bioavailability, pharmacokinetics, and pharmacodynamics. It is currently the subject of four clinical trials: a Phase 2 trial assessing its effect on multiple measures of muscle function in patients with Type II, Type III, or Type IV SMA, a Phase 2 trial evaluating its effect on physical function and exercise tolerance in patients with COPD, a Phase 2 trial investigating its effect on measures of respiratory function and skeletal muscle function in patients with ALS, and a Phase 1b trial investigating its effect on measures of physical function in elderly adults with limited mobility.